Overall Status

Completed (3)

Recruiting (1)

Phase

phase 1/phase 2 (2)

phase 1 (1)

Sponsor

Calibr, a division of Scripps Research (1)

Epizyme, Inc. (1)

Millennium Pharmaceuticals, Inc. (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University (1)

Collaborator

Intervention

alisertib (mln8237) (1)

cd19 car-t expressing il7 and ccl19 (1)

clbr001 and swi019 (1)

rituximab (1)

tazemetostat (1)

vincristine (1)

Study Documents

Intervention Type

drug (2)

biological (1)

combination product (1)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (3)

Observational [Patient Registry] (1)

transformed follicular lymphoma

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in United States

Recruiting

Relapsed/Refractory B-cell Lymphomas
+11 more

CLBR001 and SWI019

Duarte, California
+7 more

Jul 26, 2022

B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2) Trial in Worldwide

Completed

B-cell Lymphomas (Phase 1)
+5 more

Tazemetostat

Birmingham, Alabama
+51 more

Dec 8, 2021

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Transformed Follicular Lymphoma Trial in Hangzhou (CD19 CAR-T Expressing

Completed

Diffuse Large B-cell Lymphoma
+3 more

CD19 CAR-T Expressing IL7 and CCL19

Hangzhou, State..., China

Hui Liu

Apr 4, 2021

DLBCL, Transformed Follicular Lymphoma, Mantle Cell Lymphoma Trial in Worldwide (Alisertib (MLN8237), Rituximab, Vincristine)

Completed

Has Results

Diffuse Large B-Cell Lymphoma
+3 more

Alisertib (MLN8237)
+2 more

Tucson, Arizona
+24 more

Feb 27, 2018